USD 16.40 Billion
Report ID:
SQMIG35H2171 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|Tables:
61
|Figures:
75
Global Antibody production Market size was valued at USD 16.40 Billion in 2022 and is poised to grow from USD 18.52 Billion in 2023 to USD 48.88 Billion by 2031, at a CAGR of 12.9% during the forecast period (2024-2031).
The purpose of the antibody production market is to meet the growing demand for antibodies that can be used in the development of targeted therapies, diagnostics, and vaccines. With the advancements in biotechnology and the increasing understanding of diseases at the molecular level, there is a rising need for specific and effective antibodies. These antibodies are essential tools in studying disease mechanisms, identifying biomarkers, and developing personalized medicine approaches. A key driving factor in the antibody production market is the increasing prevalence of chronic and infectious diseases, which has fueled the demand for targeted therapies and diagnostics. Antibodies have shown promising results in treating diseases such as cancer, autoimmune disorders, and infectious diseases. The growing focus on precision medicine and personalized treatment approaches has further contributed to the market's growth. Despite these challenges, there are several opportunities in the antibody production market.
Technological advancements, such as the development of recombinant DNA technology and high-throughput screening methods, have improved the efficiency and scalability of antibody production. The global antibody production market serves a vital role in the healthcare and pharmaceutical industries by providing essential tools for diagnostics, therapeutics, and research. The market's growth is driven by the increasing demand for targeted therapies, diagnostics, and the pursuit of personalized medicine approaches. While challenges exist, technological advancements and evolving healthcare needs create opportunities for innovation and expansion in the antibody production market.
US Antibody Production Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 16.40 Billion
Largest Segment
Monoclonal Antibody
Fastest Growth
Monoclonal Antibody
Growth Rate
12.9% CAGR
To get more reports on the above market click here to Buy The Report
The global antibody production market is segmented on the basis of type, process, and region. Based on classification by type, the market is segmented into Monoclonal Antibody, and Polyclonal Antibody. By Process, the market is segmented into Upstream Processing, Downstream Processing. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Analysis by Type
In 2022, the monoclonal antibody segment is projected to dominate the antibody production market, accounting for a significant revenue share of 63.25%. This segment is also expected to exhibit a higher compound annual growth rate (CAGR) of 13.58% during the period of 2023-2030. The growth of this segment can be attributed to the increasing investments in research on monoclonal antibodies and the introduction of novel antibody-based products. A notable example is the investment made by Eli Lilly, a US-based pharmaceutical company, in March 2023. They have allocated nearly USD 1 billion to establish a monoclonal antibody manufacturing plant in Ireland, with production expected to commence by 2026. This investment indicates the significant focus and potential of the monoclonal antibody segment in the market.
The polyclonal antibody segment is expected to experience substantial growth in the forecast period. This is primarily due to several advantages associated with polyclonal antibodies, including a smoother production process and their availability at a lower cost. The growing demand for diagnostic tests for prevalent diseases further contributes to the growth of this segment. Moreover, advancements in technology and techniques for polyclonal antibody production, such as recombinant DNA technology and transgenic animal models, are likely to fuel the expansion of this segment. Notably, polyclonal antibodies can be produced more quickly and cost-effectively compared to monoclonal antibodies, as they do not require the complex cell culture and screening processes involved in monoclonal antibody production. This makes polyclonal antibodies an attractive option in terms of efficiency and cost-effectiveness for various applications in the antibody production market.
Analysis by Process
In 2022, The downstream segment emerged as the dominant sector in the antibody production market capturing a significant market share of 67.04%. This segment is expected to exhibit a faster compound annual growth rate (CAGR) of 13.48% from 2023 to 2030. The downstream process plays a crucial role in ensuring the quality, safety, efficacy, purity, and identity of antibodies. It encompasses various steps and technologies that contribute to efficient bio-manufacturing and enable continuous innovation. Technological advancements have significantly improved the downstream process, with the introduction of single-use sensors, membrane chromatography technology, remote monitoring, and data analytics. These advancements enhance operational efficiency, increase productivity, and improve product quality. For instance, in March 2019, GE Healthcare and Amgen collaborated on a digital data exchange program to explore advancements in bio-manufacturing and better understand raw material variability. This collaboration reflects the industry's commitment to leveraging technology to optimize the downstream process and enhance overall antibody production capabilities.
The upstream process segment is projected to experience substantial growth in the forecast period. This can be attributed to significant investments and advancements in production infrastructure by various manufacturers. Leading companies are incorporating cutting-edge bioreactors into the upstream process to ensure the delivery of high-quality end-products. For instance, on April 18, 2023, Cytiva (part of Danaher) launched the X-platform single-use bioreactors, which are designed to enhance process efficiency in upstream bioprocessing operations. The versatile X-platform is capable of producing cell and gene therapies, protein-based drugs (including monoclonal antibodies), and viral vectors. These advancements in upstream technologies not only enable improved production efficiency but also support the development of advanced therapies and expand the capabilities of antibody production.
To get detailed analysis on other segments, Request For Free Sample Report
In 2022, North America emerged as the leading region for the antibody production market, capturing the largest revenue share of 38.29%. This can be attributed to the presence of prominent biopharmaceutical and biotechnology companies in the United States and Canada. The region's robust healthcare infrastructure, along with substantial investments in drug discovery and research, contributes to the market's growth. The adoption of biopharmaceuticals, including antibodies, is on the rise in North America due to their efficacy, specificity, and safety. These factors drive the demand for antibody production as they are increasingly utilized in the treatment of various diseases. Furthermore, the integration of advanced technologies, such as artificial intelligence (AI) in the drug development process, is gaining momentum. Pharmaceutical companies are investing significantly in AI technology, which accelerates drug discovery and reduces costs. This technological advancement further propels the growth of the antibody production market in North America.
Asia Pacific is projected to exhibit the fastest compound annual growth rate (CAGR) of 16.14% from 2023 to 2030. The region presents untapped opportunities for market expansion. Factors such as increasing investments in research and development activities, growing demand for therapeutics and diagnostics, and a rising aging population contribute to the market's growth in Asia Pacific. Moreover, the prevalence of chronic diseases, including cancer, autoimmune disorders, and infectious diseases, is on the rise in the region. This drives the demand for antibody-based therapies and diagnostics. As a result, the Asia Pacific region holds significant potential for market growth in the antibody production sector.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers
Increasing Demand for Antibody-Based Therapeutics
Advancements in Biotechnology and Biopharmaceutical Research
Restraints
High Development and Production Costs
Stringent Regulatory Requirements
Request Free Customization of this report to help us to meet your business objectives.
The global antibody production market is highly dynamic and characterized by intense competition among key players. The market is dominated by established biopharmaceutical companies, contract research organizations (CROs), and academic institutions with significant expertise and resources in antibody production. To gain a competitive edge, companies in the antibody production market are investing heavily in research and development activities to discover and develop new antibodies with enhanced therapeutic efficacy and improved safety profiles. They are also focusing on expanding their production capacities and optimizing manufacturing processes to meet the growing demand for antibodies. Partnerships, collaborations, and strategic alliances are common strategies adopted by key players to strengthen their market position and broaden their product portfolios. For example, in 2022, AstraZeneca plc (United Kingdom) and Regeneron Pharmaceuticals Inc. (United States) entered into a collaboration to develop and commercialize novel antibody-based therapeutics.
Top Player’s Company Profiles
Recent Developments
Amgen gave the public good news in November 2023 when they released the Phase 3 findings for AMG 520. When compared to conventional chemotherapy, this bispecific antibody that targets both EGFR and VEGFR2 significantly improved progression-free survival (PFS). The benefits of AMG 520 in the treatment of patients with metastatic colorectal cancer that is KRAS wild type were particularly underlined in the study.
AstraZeneca and Daiichi Sankyo joined forces on an innovative initiative in October 2023. Together, they are developing novel cancer therapies known as antibody-drug conjugates (ADCs). AstraZeneca is an expert in ADC technology, and Daiichi Sankyo is a master at creating cancer-specific pharmaceuticals. The medical community is taking notice of this partnership.
In February 2023, Thermo Fisher Scientific launched its new CHO Cell Line, CHO-S5, which is designed for the production of high-quality monoclonal antibodies.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global antibody production market analysis, the increasing prevalence of chronic diseases, coupled with advancements in biotechnology, and rising demand for personalized medicine are the key growth drivers. The market is driven by the growing need for effective therapies and diagnostics for diseases like cancer, autoimmune disorders, and infectious diseases. The market analysis of the global antibody production market provides valuable insights into the current state of the industry, its drivers, restraints, challenges, and opportunities. It serves as a guide for market participants, investors, and stakeholders to make informed decisions and capitalize on the growing demand for antibodies in healthcare and biopharmaceutical applications. The market is driven by the growing need for effective therapies and diagnostics for diseases like cancer, autoimmune disorders, and infectious diseases. The market analysis of the global antibody production market provides valuable insights into the current state of the industry, its drivers, restraints, challenges, and opportunities. It serves as a guide for market participants, investors, and stakeholders to make informed decisions and capitalize on the growing demand for antibodies in healthcare and biopharmaceutical applications.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 16.40 Billion |
Market size value in 2031 | USD 48.88 Billion |
Growth Rate | 12.9% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Antibody Production Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Antibody Production Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Antibody Production Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Antibody Production Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35H2171
sales@skyquestt.com
USA +1 351-333-4748